The company is a Korea-based company primarily engaged in the development of therapeutics for intractable vascular and metabolic diseases. The Company researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company's drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers. The Company was established on May 12, 2016. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on July 22, 2021.
Headquarters
23-1, Hyoryeong-Ro, Seocho-Gu
Seoul; Seoul;
Contact Details: Purchase the Curacle Co.,Ltd. report to view the information.
Website: http://www.curacle.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service